DAFNA Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-307,232
| Closed | -$4.65M | – | 89 |
|
|
2022
Q3 | $4.65M | Buy |
307,232
+18,192
| +6% | +$211K | 1.25% | 28 |
|
|
2022
Q2 | $2.17M | Hold |
289,040
| – | – | 0.59% | 44 |
|
|
2022
Q1 | $2.63M | Hold |
289,040
| – | – | 0.69% | 42 |
|
|
2021
Q4 | $2.03M | Hold |
289,040
| – | – | 0.51% | 43 |
|
|
2021
Q3 | $3.29M | Hold |
289,040
| – | – | 0.87% | 29 |
|
|
2021
Q2 | $4.63M | Buy |
289,040
+13,200
| +5% | +$226K | 0.97% | 27 |
|
|
2021
Q1 | $4.93M | Sell |
275,840
-12,600
| -4% | -$218K | 1.17% | 25 |
|
|
2020
Q4 | $3.9M | Buy |
288,440
+4,000
| +1% | +$48.3K | 1.16% | 22 |
|
|
2020
Q3 | $3.35M | Buy |
284,440
+5,000
| +2% | +$60.9K | 1.09% | 23 |
|
|
2020
Q2 | $4.13M | Sell |
279,440
-14,000
| -5% | -$207K | 1.19% | 28 |
|
|
2020
Q1 | $3.96M | Buy |
293,440
+25,601
| +10% | +$486K | 1.65% | 16 |
|
|
2019
Q4 | $6.47M | Sell |
267,839
-19,909
| -7% | -$412K | 2.22% | 12 |
|
|
2019
Q3 | $5.53M | Buy |
287,748
+82,308
| +40% | +$1.89M | 2.08% | 13 |
|
|
2019
Q2 | $6.07M | Buy |
205,440
+53,670
| +35% | +$2.07M | 2.28% | 10 |
|
|
2019
Q1 | $7.21M | Buy |
151,770
+10,000
| +7% | +$440K | 3.11% | 7 |
|
|
2018
Q4 | $5.12M | Buy |
141,770
+9,000
| +7% | +$422K | 2.55% | 9 |
|
|
2018
Q3 | $8.17M | Buy |
132,770
+1,000
| +0.8% | +$64.3K | 3.36% | 6 |
|
|
2018
Q2 | $8.9M | Sell |
131,770
-1,000
| -0.8% | -$56K | 4.17% | 4 |
|
|
2018
Q1 | $7.2M | Buy |
132,770
+16,000
| +14% | +$895K | 3.5% | 7 |
|
|
2017
Q4 | $6.98M | Hold |
116,770
| – | – | 3.76% | 4 |
|
|
2017
Q3 | $5.67M | Buy |
116,770
+10,000
| +9% | +$546K | 3.52% | 7 |
|
|
2017
Q2 | $5.61M | Buy |
106,770
+60,000
| +128% | +$2.79M | 4% | 4 |
|
|
2017
Q1 | $2.12M | Sell |
46,770
-51,600
| -52% | -$2.3M | 1.79% | 19 |
|
|
2016
Q4 | $3.72M | Buy |
98,370
+6,501
| +7% | +$246K | 3.27% | 8 |
|
|
2016
Q3 | $3.47M | Sell |
91,869
-69,000
| -43% | -$1.52M | 2.41% | 9 |
|
|
2016
Q2 | $2.83M | Sell |
160,869
-18,900
| -11% | -$306K | 2.24% | 12 |
|
|
2016
Q1 | $2.19M | Buy |
179,769
+31,400
| +21% | +$497K | 1.89% | 17 |
|
|
2015
Q4 | $3.61M | Sell |
148,369
-17,300
| -10% | -$404K | 3.22% | 7 |
|
|
2015
Q3 | $2.94M | Buy |
165,669
+8,827
| +6% | +$160K | 2.92% | 7 |
|
|
2015
Q2 | $2.77M | Sell |
156,842
-3,400
| -2% | -$62.3K | 2.34% | 12 |
|
|
2015
Q1 | $5.02M | Buy |
160,242
+27,800
| +21% | +$806K | 3.86% | 6 |
|
|
2014
Q4 | $3.87M | Sell |
132,442
-12,900
| -9% | -$327K | 3.06% | 9 |
|
|
2014
Q3 | $3.01M | Buy |
+145,342
| New | +$2.87M | 3.03% | 12 |
|
DAFNA Capital Management's AERI Position: Q4 2022 in Review
DAFNA Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 307,232 shares — an estimated $4.65M sold.
DAFNA Capital Management first reported a position in AERI in Q3 2014 and held it in 33 quarters. The position peaked at $8.9M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- DAFNA Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- DAFNA Capital Management sold 307,232 Aerie Pharmaceuticals shares in Q4 2022, an estimated $4.65M.
- DAFNA Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 33 quarters.
- DAFNA Capital Management's Aerie Pharmaceuticals position peaked at $8.9M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.